HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells

被引：99

作者：

Bachleitner-Hofmann, Thomas ^{[1
]}

Sun, Mark Y. ^{[1
]}

Chen, Chin-Tung ^{[1
]}

Tang, Laura ^{[2
]}

Song, Lin ^{[2
]}

Zeng, Zhaoshi ^{[1
]}

Shah, Manish ^{[3
]}

Christensen, James G. ^{[5
]}

Rosen, Neal ^{[4
]}

Solit, David B. ^{[3
]}

Weiser, Martin R. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Program Pharmacol & Chem, New York, NY 10021 USA

[5] Jolla Labs, Pfizer Global Res & Dev, Dept Canc Res, La Jolla, CA USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2008年 / 7卷 / 11期

关键词：

D O I：

10.1158/1535-7163.MCT-08-0374

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumor cells with genomic amplification of MET display constitutive activation of the MET tyrosine kinase, which renders them highly sensitive to MET inhibition. Several MET inhibitors have recently entered clinical trials; however, as with other molecularly targeted agents, resistance is likely to develop. Therefore, elucidating possible mechanisms of resistance is of clinical interest. We hypothesized that collateral growth factor receptor pathway activation can overcome the effects of MET inhibition in MET-amplified cancer cells by reactivating key survival pathways. Treatment of MET-amplified GTL-16 and MKN-45 gastric cancer cells with the highly selective MET inhibitor PHA-665752 abrogated MEK/ mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT signaling, resulting in cyclin D1 loss and G, arrest. PHA-665752 also inhibited baseline phosphorylation of epidermal growth factor receptor (EGFR) and HER-3, which are transactivated via MET-driven receptor cross-talk in these cells. However, MET-independent HER kinase activation using EGF (which binds to and activates EGFR) or heregulin-beta 1 (which binds to and activates HER-3) was able to overcome the growth-inhibitory effects of MET inhibition by restimulating MEK/MAPK and/or PI3K/AKT signaling, suggesting a possible escape mechanism. Importantly, dual inhibition of MET and HER kinase signaling using PHA-665752 in combination with the EGFR inhibitor gefitinib or in combination with inhibitors of MEK and AKT prevented the above rescue effects. Our results illustrate that highly targeted MET tyrosine kinase inhibition leaves MET oncogene-"addicted" cancer cells vulnerable to HER kinase-mediated reactivation of the MEK/MAPK and PI3K/AKT pathways, providing a rationale for combined inhibition of MET and HER kinase signaling in MET-amplified tumors that coexpress EGFR and/or HER-3. [Mol Cancer Ther 2008;7(11):3499-508]

引用

页码：3499 / 3508

页数：10

共 42 条

[41] Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis [J].

Zhao, XJ ;

Weir, BA ;

LaFramboise, T ;

Lin, M ;

Beroukhim, R ;

Garraway, L ;

Beheshti, J ;

Lee, JC ;

Naoki, K ;

Richards, WG ;

Sugarbaker, D ;

Chen, F ;

Rubin, MA ;

Jänne, PA ;

Girard, L ;

Minna, J ;

Christiani, D ;

Li, C ;

Sellers, WR ;

Meyerson, M .

CANCER RESEARCH, 2005, 65 (13) :5561-5570

[42] An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms [J].

Zou, Helen Y. ;

Li, Qiuhua ;

Lee, Joseph H. ;

Arango, Maria E. ;

McDonnell, Scott R. ;

Yamazaki, Shinji ;

Koudriakova, Tatiana B. ;

Alton, Gordon ;

Cui, Jingrong J. ;

Kung, Pei-Pei ;

Nambu, Mitchell D. ;

Los, Gerrit ;

Bender, Steven L. ;

Mroczkowski, Barbara ;

Christensen, James G. .

CANCER RESEARCH, 2007, 67 (09) :4408-4417

← 1 2 3 4 5 →